


CCSC Roadmap

Comprehensive Care Sustainability Collaborative Roadmap for State Stakeholders

Bringing provider and payer stakeholders together in a collaborative forum has proven essential to ensuring that patients continue to receive optimal care for bleeding disorders.


The Comprehensive Care Sustainability Collaborative (CCSC) is a partnership forged between hemophilia treatment center (HTC) and payer stakeholders under the guidance of the National Bleeding Disorders Foundation (NBDF). CCSC seeks to promote high-quality, cost-effective care in the management of bleeding disorders by supporting the sustainability of the HTC-based model of comprehensive care, which is threatened by payer network exclusion and extremely limited federal funding. At least 80% of individuals with hemophilia are treated at an HTC, a sizeable share of whom have public insurance coverage¹. Bringing provider and payer stakeholders together in a collaborative forum has proven essential to ensuring that these patients continue to receive optimal care. CCSC accomplishments to date include educational outreach, presentations at professional meetings, a white paper and dedicated website, fact sheets, and annual consensus meetings among HTC and payer leadership.



For more information, visit www.CCSCHemo.com


The Vital Role of HTC in the Management of Bleeding Disorders Infrastructure

- HTCs represent the mainstay centers of excellence in the management of bleeding disorders.
- A regional network of HTCs was established by Congress under the guidance of the HRSA Maternal and Child Health Bureau (MCHB) more than 40 years ago to ensure that patients with bleeding disorders in both rural and metropolitan areas have adequate access to optimal care.
 - The Centers for Disease Control and Prevention also partners with HTCs and NBDF on educational outreach and coordinated research.²



Care Model


- HTCs are founded in the comprehensive care model, the original medical home, which addresses the clinical and psychological components of bleeding disorders via ongoing interaction with the patients and their families/caregivers.
- HTC-based care is delivered by a multidisciplinary team of onsite providers who are highly specialized in the management of bleeding disorders and includes a wide breadth of ancillary services such as physical therapy, case management, dental/oral health, psychotherapy, and social services, and patient education.
 - This model of integrated, multidisciplinary care is endorsed by a number of consensus guidelines and clinical recommendations.^{3,4}



- Some HTCs feature in-house pharmacy services that allow for the intensive management and monitoring of adherence, utilization, and dose requirements.
 - This approach prevents the fragmentation of care and facilitates more rigorous assay management in terms of prescribed versus dispensed dosing.
- Federally distributed 340B grant funding from the Health Resources & Services Administration (HRSA) serves as a source of revenue for these centers and allows for the provision of comprehensive services at a competitive price versus specialty pharmacy vendors.
- In order to access the 340B pharmacy, individuals must be patients of the center. However, the entire bleeding disorders community benefits from the existence of a nationwide network of centers by being able to access the full range of services provided and improved health outcomes.

Outcomes

- Care delivered by an HTC is associated with documented improvements in outcomes, despite the clinically complex subset of patients with bleeding disorders seen at centers across the country:
 - Reduced mortality⁵
 - Reduced emergency department (ED) utilization⁷
 - Reduced hospitalization⁶
 - Increased rates of cost-effective self-infusion/home-based infusion



The Significance of CCSC for Patient Care

- CCSC promotes the sustainability of HTC— a vital resource for individuals with bleeding disorders— and ensures that individuals in both urban and rural areas receive the care they need at the right place and at the right time, regardless of insurance type.
 - HTC-based care is guideline endorsed and represents the gold standard in terms of integrated delivery, quality, and outcomes.
 - Care delivered by an HTC is cost-effective and reduces waste of clotting factor replacement therapy.
- CCSC extends the patient advocacy efforts of NBDF to interactions with payers and augments the fair and affordable coverage of services delivered at HTCs.
 - HTC sustainability and patient access are imperiled by extenuating factors in the current US health care environment.
- CCSC membership provides state payer representatives the opportunity to advocate for their patients with bleeding disorders to receive the most high-quality, cost-effective care possible.

CCSC ensures that individuals in both urban and rural areas receive the care they need at the right place and right time, regardless of insurance type.

References

1. CDC. Hemophilia Treatment Centers. <https://www.cdc.gov/ncbddd/hemophilia/htc.html>.
2. Baker JR, et al. *Am J Public Health*. 2005;95:1910–1916.
3. NBDF. MASAC #132. <https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations>.
4. Pai M, et al. *Haemophilia*. 2016;22(Suppl 3):6–16.
5. Soucie JM, et al. *Blood*. 2000;96:437–442.
6. Soucie JM, et al. *Haemophilia*. 2001;7:198–206.
7. Okolo AL, et al. *Haemophilia*. 2019;25:456–462.

To find out about how CCSC can benefit your state-funded insurance enrollees: CONTACT > ccsc@impactedu.net

Provided by



In Partnership with



CCSC is supported by charitable donations from founding supporter Takeda, and additional support from BioMarin, Biotechnology Innovation Organization, Bleeding & Clotting Disorders Institute, CSL Behring, Genentech, Inc., Gulf States Hemophilia and Thrombophilia Center, Louisiana Center for Bleeding and Clotting Disorders, Sanofi, and Spark Therapeutics. Copay Accumulator Adjustment Program (CAAP) Outreach is supported by AbbVie, Inc.

© 2023 National Bleeding Disorders Foundation. All rights reserved.